- Childhood AML Combined with AML1-ETO Fusion Gene and c-KIT or Other Mutations Had Favorable Survival Treated By the C-Huanan AML 2015 Protocol: Study in Multicenter of South of ChinaFeng, Xiaoqin; Li, Chunfu; Li, Jian; Zheng, Yongzhi; Zheng, Mincui; Mai, Huirong; Yang, Lihua; He, Xiangling; He, Yingyi; Wen, Hong; Li, Yirong65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort studyXu, Dan; Yang, Ying; Yin, Zhao; Tu, Sanfang; Nie, Danian; Li, Yiqing; Huang, Zhenqian; Sun, Qixin; Huang, Changfen; Nie, Xiaqi; Yao, Zurong; Shi, Pengcheng; Zhang, Yu; Jiang, Xuejie; Liu, Qifa; Yu, Guopan*Blood Cancer Journal, 2023, 13(1): 168.
- Tim-3 Mutation Might Play in the Pathophysiology of Acute Myeloid LeukemiaHuang, Junwei; Liu, Qifa; Jin, Hua63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA, 2021-12-11 To 2021-12-14.
会议论文
Gene Mutation and MRD-Directed Risk Stratification Treatment Improves Long Term Survival of the Patients with AML1-ETO-Positive AML
11阅读
